Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol 8000
- Development stage
- Unknown
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral, Topical, Parenteral, Rectal
01
Overview
Polyethylene glycol 8000 (PEG 8000) is a synthetic, water-soluble polymer with a molecular weight of approximately 8000 daltons. While primarily utilized as a pharmaceutical excipient—serving as a solvent, plasticizer, surfactant, and tablet binder—it also functions as an osmotic laxative. In preclinical research, PEG 8000 has demonstrated potent chemopreventive properties against colon cancer, particularly in rat models. Its mechanism of action in this context is attributed to the induction of high osmotic pressure, which selectively inhibits the growth of proliferating cancer cells by inducing cell cycle arrest in the G0/G1 phase and causing cell shrinkage. It is manufactured by various companies including BASF and Venus Ethoxyethers.
- Brand names
- Kollisolv PEG 8000
- Other names
- PEG 8000PEG8000PEG-8000macrogol 8000macrogol8000macrogol-8000
Beyond the preview
Go deeper on polyethylene glycol 8000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol 8000.